Dr Janet Maguire
Dr Janet Maguire
Position(s):
Senior Research Associate, University of Cambridge;
Fellow of Queens' College, University of Cambridge.
Email: jjm1003@medschl.cam.ac.uk
Tel: 01223 762579
Research Description
My research focuses on the pharmacology of established and novel G-protein coupled receptors (GPCRs) and their endogenous ligands in the human cardiovascular system. I am particularly interested in the role of GPCRs in vascular reactivity and how these may change with disease. An ongoing interest is in the endothelin system and the relative contribution of the two endothelin receptor subtypes to mediate the detrimental effects of endothelin in for example atherosclerosis and pulmonary arterial hypertension. Current research is on the chemokine GPCR CCR5, an important co-receptor for HIV-1 infection that has an emerging role in the initiation and development of atherosclerosis. The objective is to use human tissues and animal models to provide proof of principle that blockade of CCR5 will be atheroprotective, reducing both vasospasm and the development of intimal hyperplasia. If our data support this hypothesis, then the availability of the first selective antagonist introduced for clinical use in HIV infection allows for the rapid translation of this drug class into a new therapeutic area.
Funding
Recent Publications
Jones K, Maguire JJ, Davenport AP.
Chemokine receptor CCR5: from AIDS to atherosclerosis. Br J Pharmacol. 2011;162(7):1453-1469.Kirby HR, Maguire JJ, Colledge WH, Davenport AP.
International Union of Basic and Clinical Pharmacology. LXXVII. Kisseptin receptor nomenclature, distribution and function. Pharmacol Rev. 2010;62:565-578.Pitkin SL, Maguire JJ, Kuc RE, Davenport AP.
Modulation of the apelin/APJ system in heart failure and atherosclerosis in man. Br J Pharmacol, 2010;160:1785-1795.Kelland NF, Kuc RE, McLean DL, Azfer A, Bagnall AJ, Gray GA, Gulliver-Sloan FH, Maguire JJ, Davenport AP, Kotelevtsev YV, Webb DJ.
Endothelial cell-specific ETB receptor knockout: autoradiographic and histological characterisation and crucial role in the clearance of endothelin-1. Can J Physiol Pharmacol. 2010;88:644-651.Pitkin SL, Maguire JJ, Colledge WH, Davenport AP.
International Union of Basic and Clinical Pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology and function. Pharmacol Rev. 2010;62:331-342.Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP.
[Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension. 2009;54:598-604.Mitchell JD, Maguire JJ, Davenport AP.
Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S. Br J Pharmacol. 2009;158:87-103.Maguire JJ, Parker WA, Foord SM, Bonner TI, Neubig RR, Davenport AP.
International Union of Pharmacology. LXXII. Recommendations for trace amine receptor nomenclature. Pharmacol Rev. 2009;61:1-8.Mitchell JD, Maguire JJ, Kuc RE, Davenport AP.
Expression and vasoconstrictor function of anorexigenic peptides neuromedin U-25 and S in the human cardiovascular system. Cardiovasc Res. 2009;81:353-361.Maguire JJ, Kuc RE, Kleinz MJ, Davenport AP.
Immunocytochemical localization of the urotensin-II receptor, UT, to rat and human tissues: relevance to function. Peptides 2008;29:735-742.